Beijing Stock Exchange To Roll Out Red Carpet For First Vaccine Firm's Debut
Chinese vaccine developer Beijing Health Guard Biotechnology is seeking to go public on the newly minted Beijing Stock Exchange, against a backdrop of very few biotechs having tried this route to reach public investors.
You may also be interested in...
In immuno-oncology and beyond, Chinese investors are setting their sights on new targets in the biopharma arena.
Full-Life’s acquisition of Focus-X came after two other Chinese biotechs leaped into the fray for a leading position in China’s nascent radionuclide therapy market.
A China returnee CEO has raised roughly $50m for his bioventure that is looking to clinically validate and commercialize an RNA activation platform he co-discovered while working in the US.